SEATTLE–(BUSINESS THREAD)–Omeros Corporation (NASDAQ: OMER ), today announced that the company will release its second quarter financial results for the period ended June 30, 2022, on Tuesday, August 9, 2022, after the market closes . Omeros management will host a conference call and webcast later today at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss financial results, as well as recent developments and highlights.
Details of the conference
To access the live conference call by telephone, dial (833) 634-2592 from within the United States and Canada or (412) 902-4100 internationally and ask to be placed on the Omeros earnings call. Please dial approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week after the call and can be accessed by dialing (877) 344-7529 from the United States, (412) 317-0088 internationally and (855) 669-9658 from Canada. The play access code is 4990130.
To access the live or later archived webcast of the conference call online, go to the Omeros website at https://investor.omeros.com/upcoming-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing protein and small molecule therapeutics for large market and orphan indications targeting immunological disorders, including complement-mediated diseases, cancers and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor, narsoplimab, targets the complement lectin pathway and is the subject of a biologics license application pending before the FDA for the treatment of associated thrombotic microangiopathy to hematopoietic stem cell transplantation (HSCT-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, the Omeros inhibitor of MASP-3, the key activator of the alternative complement pathway, is advancing clinical programs in paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more information about Omeros and its programs, visit www.omeros.com.
[ad_2]
Source link
